GLP1R and type 2 diabetes mellitus: Based on the impressive results obtained from CV trials using these drugs, guidelines from the American Diabetes Association have undergone an epochal turning, because, without taking into account the level or individualized target of HbA1c, they recommend GLP-1 RAs for T2DM patients with established atherosclerotic CVD or at high risk thereof [188].